Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWhy This Matters for Your Career
Novartis is hiring 2 roles related to this product
External Resources
EPLERENONE by Novartis is aldosterone, a component of the renin-angiotensin-aldosterone-system (raas). Approved for hypertension, to lower blood pressure. First approved in 2008.
Drug data last refreshed 20h ago
aldosterone, a component of the renin-angiotensin-aldosterone-system (RAAS). Aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin II and non-RAAS mediators such as adrenocorticotropic hormone (ACTH) and potassium. Aldosterone…
Worked on EPLERENONE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.
Pharmacokinetics Study of Eplerenone Coated Tablets
Pharmacokinetics of Eplerenone Tablet
Cardiometabolic Effects of Eplerenone in HIV Infection
Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moNovartis is hiring 2 roles related to this product